ArticleCureus2025
A Brief Report on Outcomes of Metastatic Non-Small Cell Lung Cancer: A Retrospective Observational Study in a Community Practice Setting.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose Metastatic non-small cell lung cancer (mNSCLC) is associated with poor prognosis, and treatment outcomes in real-world practice differ from those observed in clinical trials. There is an unmet need for real-world data (RWD) on treatment efficacy, tolerability, and outcomes in the community setting. Patients and methods We conducted a retrospective, observational study that reviewed patient data from a community setting between January 2019 and December 2021. A total of 182 patients with stage IV metastatic NSCLC were included. Data were collected on patient demographics, performance status, molecular characteristics, treatment regimens, and survival outcomes. Results The cohort had a median age of 72.9 years, with 51.7% females, 86.8% tobacco use, and 76.9% adenocarcinoma. Median overall survival (OS) for the entire cohort was 10.4 months (including patients with therapeutic contraindication), with survival rates of 46.7%, 33.7%, and 25.4% at 1, 2, and 3 years, respectively. OS for chemotherapy + immunotherapy (17 months) was superior to chemotherapy alone (10.6 months) and immunotherapy alone (6.2 months). Three-year OS with immunotherapy + chemotherapy did not consistently improve as PD-L1 TPS percentage increased (<1% - 25%; 1-49% - 30.4%; 50-100% - 26.7%). OS with brain metastasis at diagnosis was 7.3 months. Conclusion This study provides valuable RWD of OS and treatment patterns in metastatic NSCLC patients, highlighting differences in survival compared to clinical trial outcomes. Our findings underscore the need for further research to improve outcomes of NSCLC patients treated in community practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.